Name: Vatalanib

---

Type: small molecule

---

Groups: investigational

---

Indication: Used in combination with first- and second-line chemotherapy for the treatment of metastatic colorectal cancer and non-small cell lung cancer (NSCLC).

---

Accession Number: DB04879 ( DB04879)

---

Description: Vatalanib (PTK787/ZK-222584) is a new oral antiangiogenic molecule that inhibits all known vascular endothelial growth factor receptors. Vatalanib is under investigation for the treatment of solid tumors.

---

Structure:

---

Prescription Products: Not Available

---

Generic Prescription Products: Not Available

---

Over the Counter Products: Not Available

---

International Brands

• No Brands

---

Brand Names

• No Brands

---

Brand Mixtures

Brand Name	Ingredients

Brand Name	Ingredients

---

Categories

• Antineoplastic Agents
• Protein Kinase Inhibitors

Indication: Used in combination with first- and second-line chemotherapy for the treatment of metastatic colorectal cancer and non-small cell lung cancer (NSCLC).

---

Pharmacodynamics: Not Available

---

Mechanism of action: Vatalanib potently inhibits vascular endothelial growth factor (VEGF) receptor tyrosine kinases, important enzymes in the formation of new blood vessels that contribute to tumor growth and metastasis.

---

Absorption: Rapid onset of absorption

---

Volume of distribution: Not Available

---

Protein binding: Not Available

---

Metabolism: Not Available

---

Route of elimination: Not Available

---

Half life: Approximately 6 hours.

---

Clearance: Not Available

---

Toxicity: Not Available

---

Affected organisms

• Not Available

---

SNP Mediated Adverse Drug Reactions

• Not Available

Manufacturers:

• Not Available

---

Packagers:

• Not Available

---

Dosage forms

Form	Route	Strength

Form	Route	Strength

---

Prices

Unit description	Cost	Unit

Unit description	Cost	Unit

---

Patents

Country	Patent Number	Approved	Expires (estimated)

Drug Interactions

Drug	Interaction

Drug	Interaction

---

Food Interactions:

• Not Available

Kingdom: Organic compounds

---

Super Class: Not Available

---

Class: Not Available

---

Sub Class: Not Available

---

Direct Parent: Not Available

---

Alternative Parents:

• Aminopyridazines
• Aryl chlorides
• Azacyclic compounds
• Chlorobenzenes
• Heteroaromatic compounds
• Hydrocarbon derivatives
• Imidolactams
• Organochlorides
• Pyridines and derivatives
• Secondary amines

---

substituent:

• Amine
• Aminopyridazine
• Aromatic heteropolycyclic compound
• Aryl chloride
• Aryl halide
• Azacycle
• Benzenoid
• Chlorobenzene
• Halobenzene
• Heteroaromatic compound
• Hydrocarbon derivative
• Imidolactam
• Monocyclic benzene moiety
• Organochloride
• Organohalogen compound
• Organonitrogen compound
• Phthalazine
• Pyridazine
• Pyridine
• Secondary amine

Synthesis Reference: Not Available

---

General Reference: # Yamamoto A, Watanabe H, Sueki H, Nakanishi T, Yasuhara H, Iijima M: Vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK 222584 inhibits both the induction and elicitation phases of contact hypersensitivity. J Dermatol. 2007 Jul;34(7):419-29. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17584317 # Lijnen HR, Van Hoef B, Kemp D, Collen D: Inhibition of vascular endothelial growth factor receptor tyrosine kinases impairs adipose tissue development in mouse models of obesity. Biochim Biophys Acta. 2007 Sep;1770(9):1369-73. Epub 2007 Jun 15. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17616257 # Jost LM, Gschwind HP, Jalava T, Wang Y, Guenther C, Souppart C, Rottmann A, Denner K, Waldmeier F, Gross G, Masson E, Laurent D: Metabolism and disposition of vatalanib (PTK787/ZK-222584) in cancer patients. Drug Metab Dispos. 2006 Nov;34(11):1817-28. Epub 2006 Aug 1. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16882767

---

External Links:

Resource	Link

Resource	Link

---

ATC Codes:

• Not Available

---

AHFS Codes:

• Not Available

---

MSDS: Download